2. Search Result
Search Result
Results for "

voltage dependence

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

1

Peptides

7

Isotope-Labeled Compounds

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0185
    Lidocaine
    Maximum Cited Publications
    22 Publications Verification

    Lignocaine

    		 Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine
  • HY-B0185A
    Lidocaine hydrochloride
    Maximum Cited Publications
    22 Publications Verification

    Lignocaine hydrochloride

    		 Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor .
    Lidocaine hydrochloride
  • HY-B0262
    Methocarbamol
    1 Publications Verification

    		 Sodium Channel Neurological Disease
    Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .
    Methocarbamol
  • HY-B0185B
    Lidocaine hydrochloride hydrate
    15+ Cited Publications

    Lignocaine hydrochloride hydrate

    		 Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine hydrochloride hydrate
  • HY-B0185S1
    Lidocaine-d10

    		Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine-d10
  • HY-W357818
    Glycinexylidide

    GX

    		 Sodium Channel ERK MEK NF-κB Drug Metabolite Cancer
    Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local agent that can suppress or relieve pain, that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease .
    Glycinexylidide
  • HY-B0185AS
    Lidocaine-d10 hydrochloride

    		Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine-d10 (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia .
    Lidocaine-d10 hydrochloride
  • HY-B0185R
    Lidocaine (Standard)
    15+ Cited Publications

    Lignocaine (Standard)

    		 Reference Standards Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine (Standard) is the analytical standard of Lidocaine. This product is intended for research and analytical applications. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine (Standard)
  • HY-P1073
    ProTx-I

    		Calcium Channel Potassium Channel Sodium Channel TRP Channel Neurological Disease Cancer
    ProTx-I is a toxin derived from Thrixopelma pruriens and a peptide inhibitor targeting TTX-resistant sodium channels. ProTx-I interacts with voltage sensors of multiple domains such as NaV1.7, reduces neuronal excitability through allosteric modulation of channel gating and alteration of voltage dependence. The IC50 values of ProTx-I against human NaV1.7, NaV1.2, NaV1.6, and NaV1.5 are 95 nM, 104 nM, 21 nM, and 358 nM, respectively; ProTx-I also potently inhibits Ba 2+ currents of hCav3.1, while its inhibitory potency against hCav3.2 is approximately 160-fold lower. ProTx-I is applicable to the research of chronic pain .
    ProTx-I
  • HY-100547
    IEM-1754

    		iGluR Neurological Disease
    IEM-1754, a dicationic adamantane derivative, is a potent blocker of open channels of native ionotropic glutamate receptors including quisqualate-sensitive receptors in insect muscles, NMDAR in cultured rat cortical neurons, and AMPAR in freshly isolated hippocampal cells. IEM-1754 shows anticonvulsant potency in vivo .
    IEM-1754
  • HY-B0185AS1
    Lidocaine-d6 hydrochloride

    Lignocaine-d6 hydrochloride

    		 Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine-d6 (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor .
    Lidocaine-d6 hydrochloride
  • HY-B0262R
    Methocarbamol (Standard)

    		Reference Standards Sodium Channel Neurological Disease
    Methocarbamol (Standard) is the analytical standard of Methocarbamol. This product is intended for research and analytical applications. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .
    Methocarbamol (Standard)
  • HY-B0185S
    Lidocaine-d10 N-Oxide

    		Isotope-Labeled Compounds Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    N-Oxide Lidocaine-d10 is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine-d10 N-Oxide
  • HY-B0185G
    Lidocaine

    Lignocaine

    		 Apoptosis Sodium Channel MEK ERK NF-κB Cancer
    Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine
  • HY-107697
    N20C hydrochloride

    		iGluR Neurological Disease
    N20C hydrochloride is a selective and noncompetitive open NMDA receptor open channel blocker, with micromolar affinity, fast on-off blockade kinetics, and strong voltage dependence. Neuroprotective activity .
    N20C hydrochloride
  • HY-B0262S1
    Methocarbamol-d3

    		Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Methocarbamol-d3 is the deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .
    Methocarbamol-d3
  • HY-B0262S2
    Methocarbamol-13C,d3

    		Isotope-Labeled Compounds Sodium Channel Neurological Disease
    Methocarbamol- 13C,d3 is the 13C- and deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .
    Methocarbamol-13C,d3
  • HY-B0185S2
    Lidocaine-d6

    Lignocaine-d6

    		 Isotope-Labeled Compounds Apoptosis Sodium Channel NF-κB MEK ERK Cardiovascular Disease Cancer
    Lidocaine-d6 (Lignocaine-d6) is deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine-d6
  • HY-B0185BR
    Lidocaine hydrochloride hydrate (Standard)

    Lignocaine hydrochloride hydrate (Standard)

    		 Reference Standards Sodium Channel MEK ERK NF-κB Apoptosis Cardiovascular Disease Cancer
    Lidocaine (hydrochloride hydrate) (Standard) is the analytical standard of Lidocaine (hydrochloride hydrate). This product is intended for research and analytical applications. Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia .
    Lidocaine hydrochloride hydrate (Standard)
  • HY-131691
    NMDAR blocker 1

    		iGluR Calcium Channel Neurological Disease
    NMDAR blocker 1 is an NMDA receptor channel blocker with an IC50 of 5.0 μM. NMDAR blocker 1 exhibits fast on-off blockade kinetics and strong voltage dependence, and does not compete with glutamate or glycine. NMDAR blocker 1 prevents glutamate/NMDA-induced intracellular Ca 2+ overload, modulates the glutamate-nitric oxide-cGMP pathway. NMDAR blocker 1 prevents in vitro excitotoxic neurodegeneration of cultured cerebellar and hippocampal neurons. NMDAR blocker 1 attenuates excitotoxic insult in an mouse model of hyperammonemia-induced excitotoxicity. NMDAR blocker 1 can be used for the research of neurodegenerative diseases .
    NMDAR blocker 1
  • HY-115596
    BTT-369

    		Calcium Channel Neurological Disease
    BTT-369 is a CaVα1·CaVβ3 protein-protein complex antagonist with a Ki of 2.0 μM. BTT-369 inhibits CaV2.2 currents, with an apparent IC50 value of 31 μM. BTT-369 disrupts the interaction between CaVα1 and CaVβ3 subunits. BTT-369 reduces the current density of CaV2.2, and shifts the voltage dependence of steady-state inactivation and activation of CaV2.2 to more positive potentials. BTT-369 alleviates mechanical hyperalgesia in a rat model of tibial nerve injury. BTT-369 can be used for the study of neuropathic pain .
    BTT-369

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: